Related Experiment Video
Updated: Sep 27, 2025
08:49
Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
Published on: May 11, 2018
9.5K
Direct Cardiac Compression Devices to Augment Heart Biomechanics and Function
Jean Bonnemain1,2, Pedro J Del Nido3, Ellen T Roche1,4
1Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Annual Review of Biomedical Engineering
|April 8, 2022
Summary
Direct cardiac compression (DCC) devices offer a novel approach to treating heart failure by avoiding blood contact, potentially reducing complications associated with current mechanical circulatory support (MCS) systems.
Area of Science:
- Cardiovascular Medicine
- Biomedical Engineering
- Medical Devices
Background:
- End-stage heart failure treatment has advanced with medical therapies, transplantation, and mechanical circulatory support (MCS).
- Current MCS devices have limitations due to blood contact, leading to complications like thrombosis, hemorrhage, stroke, and hemolysis.
- Direct Cardiac Compression (DCC) devices emerged as an alternative to minimize blood-device interactions.
Purpose of the Study:
- To review the fundamental concepts of DCC technology.
- To present existing and emerging DCC devices in research and commercialization.
- To discuss the requirements for clinical translation and adoption of DCC.
Main Methods:
- Literature review of DCC concepts, foundational devices, and recent advancements.
- Analysis of research and commercialization stages of DCC technology.
- Discussion of clinical translation and adoption milestones.
Main Results:
- DCC devices aim to support the failing heart by external compression, circumventing blood contact.
- A range of DCC devices, from foundational designs to those in advanced development, have been conceptualized and created.
- Key milestones for clinical adoption include demonstrating safety, efficacy, and overcoming engineering challenges.
Conclusions:
- DCC represents a promising alternative to traditional MCS for end-stage heart failure.
- Further research and development are crucial for the successful clinical implementation of DCC devices.
- Addressing challenges in device design, biocompatibility, and surgical implantation is essential for widespread adoption.
Keywords:
cardiac assist devicescardiac biomechanicsdirect cardiac compressionheart failuremechanical circulatory supportsoft roboticsMore Related Videos
06:10Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
3.4K
07:39Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
Published on: August 16, 2021
3.8K
Related Concept Videos
01:30Cardiomyopathy II: Dilated Cardiomyopathy
43
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
43
01:22Heart Failure VI: Adjunct Therapies
45
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
45
01:29Cardiomyopathy V: Interprofessional Care
51
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
51
01:30Heart Failure V: Medical Management
36
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
36
01:22Heart Failure Drugs: β-Blockers
451
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
451
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
75
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
75